Navigation Links
Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights
Date:5/8/2008

BERKELEY HEIGHTS, N.J., May 8 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) today announced financial results for the quarter ended March 31, 2008. From the beginning of the year, the Company has recorded significant milestones including the following:

-- AGENDA Phase 3 trial passes initial DSMB

-- Oral G4544 for bone disease completes single dose-trial in 505(b)(2)

strategy

-- Tesetaxel in-licensed -- leading oral taxane and new clinical-stage

product

-- FDA provides regulatory guidance for Genasense in CLL

-- Company restructures to conserve cash

-- Genta will seek buyer for Ganite and terminates c-myb antisense program

"Genta has successfully diversified with three high-value clinical-stage products in our portfolio," noted Dr. Raymond P. Warrell, Jr., Genta's Chairman and Chief Executive Officer. "The Phase 3 trial of Genasense in melanoma has now enrolled more than 25% of its target, we expect accrual completion this year, and positive results should enable worldwide regulatory filings in 2009. During the quarter, FDA provided substantial guidance on the development of each of our compounds. With G4544, an internally developed compound for skeletal diseases, we have the opportunity to submit a NDA for a product via a streamlined 505(b)(2) regulatory strategy. Our in-licensing of worldwide rights to tesetaxel has provided us with a leading oral taxane that addresses a very large and well-characterized market. This portfolio includes unique compounds that offer significant partnering opportunities to accelerate their development."

Highlights and updates of the Genta programs appear below.

Genasense: The Leading Antisense Drug in Clinical Development

Genasense in Melanoma: Genta is currently enrolling patients with advanced melanoma in a randomized Phase 3 trial of Genasense plus chemotherapy, known as AGENDA. The study is designed to c
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Syngenta Licenses Chromatin Gene Stacking Technology
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
5. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
6. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
7. Genta Receives NASDAQ Non-Compliance Notice
8. Genta Receives Notice of Non-Compliance With NASDAQ Rule
9. Genta Incorporated to Present at the BIO CEO & Investor Conference
10. Genta Announces Common Stock Offering of Approximately $3.1 Million
11. Genta Announces Senior Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Israel , September 2, 2015 ... intent of the National Institute of Allergy and Infectious Diseases ... within the Department of Health and Human Services (HHS), to ... the United States in the 2015-16 ... flu vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, which ...
(Date:9/2/2015)... Diego, CA (PRWEB) , ... September 02, 2015 ... ... troubleshooting faults in manufacturing equipment, to creating professional commercial video content, to analysis ... detailed views of fascinating events that go by too quickly to process with ...
(Date:9/1/2015)... EDISON, N.J. , Sept. 1, 2015  ContraVir ... focused on the development and commercialization of targeted antiviral ... Rodman & Renshaw 17 th Annual Global Investment ... taking place September 8-10, 2015 at The St. Regis ... James Sapirstein , Chief Executive ...
(Date:9/1/2015)... ... 01, 2015 , ... VetStem Biopharma announces new Clinical Research ... problems can be caused by injuries and abnormalities of the cervical spine. Arthritic ... of the spinal cord itself. This can manifest itself as any or all ...
Breaking Biology Technology:BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3
... Laboratories,Inc., a global provider of medical, nutraceutical, consumer ... a letter from The,Nasdaq Stock Market informing the ... of the Company, and would suspend trading in ... business on Thursday, August,16, 2007. As previously ...
... in Number and Viability of Stem Cells Derived from ... BioLife,s Patented Preservation Media, BOTHELL, Wash., Aug. 17 ... developer and marketer of,proprietary hypothermic storage and cryopreservation media ... as the exclusive,supplier of preservation media to the New ...
... Mass., Aug. 17 Indevus,Pharmaceuticals, Inc. (Nasdaq: ... approvable letter from the U.S. Food and Drug ... valrubicin for intravesical,instillation, is the only product approved ... carcinoma in situ (CIS) of the,urinary bladder. ...
Cached Biology Technology:Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets 2BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc. 2BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc. 3Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 2Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 3Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 4
(Date:9/2/2015)... FELTON, California , September 2, 2015 /PRNewswire/ ... with the security purpose implied in a system ... hand geometry, voice, signature, iris, vein, DNA and ... crimes has forced to develop such system which ... by username, password, PIN, Patterns and tokens are ...
(Date:8/26/2015)... India , August 26, 2015 ... Three, Four, and Five Factor), Application (Travel & Immigration, ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... Billion by 2020, growing at a CAGR of 17.7% ... Tables and 82 F igures spread through 169 ...
(Date:8/20/2015)... 2015   Sensory, Inc ., a Silicon ... experience and security of consumer electronics through state-of-the-art ... its TrulySecure™ is the first multimodal ... FIDO Certified™. The FIDO (Fast Identification ... FIDO UAF (Universal Authentication Framework) 1.0 specifications, which ...
Breaking Biology News(10 mins):Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 2Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5
... a new approach for surveying phosphorylation, a process that ... several key cellular signaling events. The research, published by ... journal Molecular Cell , describes the regulation of ... an important role in cancer cell invasion. Many ...
... if you stare at the downward motion of a waterfall ... appear to drift upward. MIT neuroscientists have found that ... visual perception but also in our tactile perception, and that ... you feel the world can actually change how you see ...
... The seventh Basel Computational Biology Conference 2009 "Molecular ... 150th anniversary of the publication of "On the ... Manolis Dermitzakis, Wellcome Trust Sanger Institute, Cambridge, UK;, ... Eyre-Walker, University of Sussex, UK;, Laurent Excoffier, SIB ...
Cached Biology News:New method for detection of phosphoproteins reveals regulator of melanoma invasion 2MIT: How you feel the world impacts how you see it 2
Identify and characterize Phosphoinositide (PI(4,5)P2) binding...
... These skirted micro test tubes are used ... polypropylene, these tubes have uniform walls for ... with separate O-ring screw caps. The O-rings ... have an operating range from -55 to ...
... Sac-Cel (Second Antibody Coated CELlulose) was developed ... of Dartford, Kent, one of the earliest ... IDS acquired the product range in 1987. ... clinical biochemists developing their own "in house" ...
Determine relative degree of protein binding to phosphoinositides...
Biology Products: